Ratings ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
67.25 ^USD	+0.21%		+2.89%	+21.96%

03/05	Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing	MT
17/04	Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With an expected P/E ratio at 51.86 and 32.65 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ANI PHARMACEUTICALS, INC.	+21.96%	1.41B	C-
ELI LILLY AND COMPANY	+26.08%	662B	C+
NOVO NORDISK A/S	+21.85%	546B	B
JOHNSON & JOHNSON	-4.77%	359B	C+
MERCK & CO., INC.	+16.97%	323B	B-
ABBVIE INC.	+5.69%	290B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+3.65%	198B	B-
ROCHE HOLDING AG	-11.12%	194B	A+
AMGEN INC.	+8.08%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes